Where Regenxbio Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analyst ratings for Regenxbio (NASDAQ:RGNX) show a mix of bullish to bearish sentiments, with recent actions including maintains, raises, and announces from firms like Stifel and Barclays. The average 12-month price target for RGNX is $38.22, up from $37.75, with a high estimate of $55.00 and a low of $21.00. Financial indicators reveal challenges in revenue growth and debt management, but a strong net margin. The company's focus is on gene therapy for various diseases, with most revenue from the U.S.
April 12, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analyst ratings for RGNX vary, with a new average price target of $38.22, indicating a positive outlook. Financial challenges persist, but the strong net margin is a positive sign.
The mixed analyst ratings with a slight increase in the average price target suggest optimism about RGNX's future performance. Despite the financial challenges highlighted, the strong net margin and the company's focus on gene therapy for various diseases could drive investor interest and potentially boost the stock price in the short term. The detailed analysis by multiple analysts and the adjustments in price targets reflect a nuanced view of the company's prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100